Tokyo, Japan

Yasunobu Ushiki


 

 

Average Co-Inventor Count = 10.4

ph-index = 2

Forward Citations = 6(Granted Patents)


Location History:

  • Saitama, JP (2015)
  • Toshima-ku, JP (2015)
  • Tokyo, JP (2012 - 2018)

Company Filing History:


Years Active: 2012-2018

Loading Chart...
Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Yasunobu Ushiki: Innovator in Pharmaceutical Compounds

Introduction

Yasunobu Ushiki is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, holding a total of 5 patents. His work focuses on developing innovative compounds that address various medical challenges.

Latest Patents

Among his latest patents, Ushiki has developed a phenyl tetrahydroisoquinoline compound substituted with heteroaryl. This compound exhibits an excellent NHE3 inhibitory effect, which is crucial for certain therapeutic applications. Additionally, he has created a macrolide derivative that is effective against erythromycin-resistant bacteria, including resistant pneumococci, streptococci, and mycoplasmas.

Career Highlights

Throughout his career, Ushiki has worked with notable companies such as Taisho Pharmaceutical Co., Ltd. and Toyama Chemical Co., Ltd. His experience in these organizations has allowed him to refine his expertise in pharmaceutical innovation and contribute to the development of effective medical treatments.

Collaborations

Ushiki has collaborated with esteemed colleagues, including Yasuhiro Tsutsui and Fumihito Ushiyama. These partnerships have fostered a collaborative environment that enhances the potential for groundbreaking discoveries in the pharmaceutical industry.

Conclusion

Yasunobu Ushiki's contributions to pharmaceutical innovation are noteworthy, with a focus on developing compounds that address critical health issues. His work continues to impact the field positively, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…